Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial.

Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio 44106, USA.
The Journal of Clinical Psychiatry (Impact Factor: 5.14). 05/1996; 57(5):184-9.
Source: PubMed

ABSTRACT It is becoming commonly recognized that adults suffer from attention-deficit/hyperactivity disorder (ADHD). Since medications used in the past of treat adults with ADHD may be ineffective or poorly tolerated by some patients, it is important to determine if newly available medications can safely ameliorate symptoms of ADHD in adults.
An open clinical trial was undertaken to examine whether venlafaxine was safe and effective in the treatment of adults with ADHD. Ten subjects who met DSM-IV criteria for ADHD were enrolled in this 8-week trial. Individuals were started on 37.5 mg of venlafaxine b.i.d. If moderate ADHD symptoms persisted at the end of Week 4, the dose of venlafaxine was increased to 75 mg b.i.d. Assessments of ADHD symptomatology included the ADHD Rating Scale, Self-Report Version (ARS) and the Clinical Global Impressions (CGI) scale.
Nine patients completed the study. At the end of the study, 7 patients were receiving 37.5 mg b.i.d. of venlafaxine. Repeated measures ANOVA demonstrated that treatment with venlafaxine was associated with significant reductions in ADHD symptomatology (p < .02 for the ARS; p < .005 for the CGI). Of the 9 subjects who completed the trial, 7 were considered responders. Venlafaxine was well tolerated, and most patients experienced only mild side effects.
Venlafaxine may be a promising agent for the treatment of ADHD in adults. Controlled clinical trials are needed to further examine this issue.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Attention deficit hyperactivity disorder (ADHD) in adults is an increasingly recognised condition that is associated with substantial functional impairment. Adults with ADHD present with a developmental derivation of symptoms reminiscent of those in juveniles, most notably inattention and distractibility and, less commonly, hyperactivity and impulsivity. Psychiatric comorbidity with mood, anxiety, substance use and antisocial personality disorders are often found in adults with ADHD. As with children with ADHD, the mainstay of treatment in adults with the disorder is pharmacotherapy. In contrast to the vast amount of data available on the treatment of children with ADHD, there have been only a limited number of medication studies in adults with the disorder. Nine studies (n = 245) of psychostimulants and 16 studies (n = 273) of nonstimulant medications, including antidepressants, antihypertensives and amino acids, have been published. A review of the literature indicates that the majority of controlled investigations assessed the effects of psychostimulants, while nonstimulant agents have generally been studied under open conditions. Stimulant medications tend to result in a dose-related improvement in ADHD symptoms. The limited data suggest that standard dosages of antidepressants are effective. Agents with catecholaminergic activity have efficacy in ADHD, whereas those with predominately serotonergic properties appear not to be effective. The majority of studies suggest that stimulants are the most effective available agents for adults with ADHD, and these drugs remain the treatment of choice. In cases of psychiatric comorbidity, residual symptoms or adverse effects, limited data suggest benefit from combining medications. Cognitive-based psychotherapy used in association with medications may play a role in treating dynamic issues, residual symptomatology and comorbid psychopathology. Future controlled studies applying stringent diagnostic criteria and outcome methodology are necessary to define further the range of pharmacotherapeutic options for adults with ADHD.
    CNS Drugs 05/1998; 9(5). · 4.38 Impact Factor
  • Official journal of the South African Academy of Family Practice/Primary Care 08/2014; 53(2):131-134.
  • Clinical Drug Investigation 02/2000; 19(2). · 1.70 Impact Factor